MyCellHub

Executive Summary

MyCellHub, now operating as Title21 Belgium NV, is a Belgian company that developed a cloud-based Manufacturing Execution System (MES) tailored for cell and gene therapy (CGT) manufacturing. Its modular platform digitizes and manages critical GMP processes, including electronic batch records, cleaning, and environmental monitoring. By streamlining compliance and data integrity, MyCellHub addresses a key bottleneck in the rapidly growing CGT sector, where manual or legacy systems hinder scalability. The company is currently being integrated into Title21 Health Solutions, a broader digital health platform, which could expand its market reach and product capabilities. As CGT manufacturing scales up, demand for specialized digital solutions is rising. MyCellHub's early focus on this niche positions it to capture market share, but the integration with Title21 introduces execution risk. The company's private status limits visibility into financial performance, though its technology's relevance to a high-growth industry suggests potential. Near-term catalysts include the completion of Title21 integration, new customer wins, and product enhancements. However, without disclosed funding or revenue metrics, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q3 2026Completion of integration into Title21 Health Solutions80% success
• Q4 2026New customer adoption of MES platform65% success
• Q1 2027Product release with enhanced environmental monitoring capabilities70% success